Felzartamab (MOR202): An Anti-CD38 Antibody Betting That Depleting Plasma Cells Can Rescue the Kidney (September 19, 2026)
Table of Contents
- Shutting down the factory instead of mopping up the mess
- Why the kidney is the proving ground
- IgA nephropathy: rapid drops in protein that outlast the drug
- Membranous nephropathy and a first for transplant rejection
- How it differs from the other new kidney immunology drugs
- Who owns it, and where it came from
- The caveats worth keeping in view
Shutting down the factory instead of mopping up the mess
Most treatments for antibody-driven disease work downstream. They neutralize a harmful antibody after it is made, or block one of the signals it sets off. Felzartamab, known by its development code MOR202 (and TJ202 in Greater China), tries something more radical: it goes after the cells that build the antibodies in the first place. Those cells - plasma cells and their younger cousins, plasmablasts - carry a protein called CD38 at very high density on their surface. Felzartamab is a fully human antibody that latches onto CD38 and flags these cells for destruction by the immune system. Deplete the factory, the reasoning goes, and you stop producing the faulty antibodies that cause the damage. It is a strategy with a strong pedigree: anti-CD38 antibodies such as daratumumab and isatuximab are already mainstays of treatment in multiple myeloma, a cancer of plasma cells. Felzartamab takes that same target and points it at a very different problem - the kidney.
Why the kidney is the proving ground
Several of the most damaging kidney diseases are unambiguously driven by antibodies, which makes them a natural fit for a plasma-cell-depleting drug. In IgA nephropathy, the most common form of primary glomerular disease worldwide, plasma cells overproduce a mis-built version of an antibody called galactose-deficient IgA1; it clumps into immune complexes that lodge in the kidney's filters and drive years of slow scarring. In primary membranous nephropathy, the immune system makes autoantibodies against a protein on the kidney's own filtering cells - most often the PLA2R receptor - and those antibodies attack the filtration barrier directly. And in antibody-mediated rejection of a transplanted kidney, the recipient's immune system produces donor-specific antibodies that injure the new organ. In each case, if you could lower the offending antibody at its source, you might change the course of the disease rather than just its symptoms. That is exactly the hypothesis felzartamab is built to test.
IgA nephropathy: rapid drops in protein that outlast the drug
In IgA nephropathy, the number doctors watch most closely is proteinuria - protein leaking into the urine, a sign that the filters are damaged and a strong predictor of long-term decline. In the Phase 2a IGNAZ study, a time-limited course of felzartamab produced rapid reductions in proteinuria that were sustained at nine months and, strikingly, still present around eighteen months after treatment had stopped. That durability - benefit persisting long after the infusions end - is the signature researchers hope for from a plasma-cell reset, and it is the reason the program moved into Phase 3. The pivotal PREVAIL trial (NCT06935357) is now randomizing roughly 454 patients to felzartamab or placebo, with the main endpoint being the percent change in proteinuria, measured by the urine protein-to-creatinine ratio (UPCR), from the start of treatment to Week 36.
Membranous nephropathy and a first for transplant rejection
In primary membranous nephropathy, the early proof-of-concept came from the M-PLACE study, an open-label trial of 31 patients with anti-PLA2R-positive disease treated with a five-month, nine-dose course. About 77% of the evaluable patients (20 of 26) saw their anti-PLA2R antibody levels fall by at least half, including people who had failed earlier immunosuppression - results echoed in the companion NewPLACE study and strong enough to earn felzartamab an FDA Breakthrough Therapy designation and a Phase 3 program. Perhaps the most novel frontier is transplant rejection. Late antibody-mediated rejection, where donor-specific antibodies slowly damage a transplanted kidney, currently has no approved treatment at all. In a Phase 2 trial published in the New England Journal of Medicine, felzartamab showed a potential benefit on rejection activity and biomarkers with an acceptable safety profile, and that signal has now advanced into the Phase 3 TRANSCEND study - a rare shot at the first therapy for a condition that transplant teams have long had to manage largely in the dark.
How it differs from the other new kidney immunology drugs
Felzartamab is arriving alongside a wave of antibody-directed kidney treatments, and the differences between them come down to where in the pathway each one acts. APRIL and BAFF blockers such as sibeprenlimab and povetacicept withdraw the survival signals that keep antibody-producing B cells alive, dialing down the supply line. FcRn inhibitors such as efgartigimod, nipocalimab, rozanolixizumab and batoclimab speed the clearance of IgG antibodies already circulating in the blood. Felzartamab occupies a third position: it removes the antibody-producing plasma cells themselves. None of these is obviously 'best' - they act on different cells, over different timescales, with different safety trade-offs - and part of what the ongoing trials will reveal is which mechanism suits which disease. What makes felzartamab distinctive is that a short, time-limited course aims for a lasting reset, rather than continuous suppression.
Who owns it, and where it came from
Felzartamab has traveled through several hands. It originated at the German biotech MorphoSys AG as MOR202, was licensed for Greater China (as TJ202) to partners that became TJ Biopharma, and was in-licensed for the rest of the world in 2022 by Human Immunology Biosciences (HI-Bio), a company built specifically around immune-mediated diseases. Biogen acquired HI-Bio in 2024, bringing felzartamab into its immunology pipeline, and in 2026 Biogen consolidated the Greater China rights from TJ Biopharma - unifying worldwide control of the asset. That corporate history matters because running three Phase 3 kidney programs simultaneously is expensive and logistically demanding; a single well-resourced owner improves the odds that the trials read out cleanly.
The caveats worth keeping in view
For all its promise, felzartamab is investigational and not approved for kidney disease anywhere; it is given only within clinical trials or supervised medical settings, by intravenous infusion. Anything sold online as 'felzartamab', 'MOR202' or 'TJ202' is unverified and unsafe - this is a hospital-administered biologic, not a supplement, nootropic or research chemical. Because it depletes plasma cells, it can lower protective antibody levels, blunt vaccine responses and raise infection risk, so live vaccines are generally avoided and infections are monitored; infusion reactions and effects on blood counts and blood-bank testing are class considerations managed by specialists. And much of the evidence so far rests on antibody and proteinuria biomarkers over short courses - encouraging surrogates, but the Phase 3 program still has to show that those early gains translate into preserved kidney function and better outcomes over years. If PREVAIL, the membranous nephropathy study and TRANSCEND deliver, felzartamab could help establish plasma-cell depletion as a broad, mechanism-based tool across antibody-mediated kidney disease.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] Biogen Highlights the Potential of Felzartamab for a Range of Immune-Mediated Diseases Including Three Phase 3 Programs in Rare Kidney Diseases - Biogen Source
- [2] Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy (IGNAZ) - Kidney International Source
- [3] Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-PLA2R-Positive Primary Membranous Nephropathy (M-PLACE) - Kidney International Reports Source
- [4] TRANSCEND: A Phase 3 Trial of the Anti-CD38 Antibody Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection - American Journal of Transplantation Source
- [5] Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy - Biogen Source
- [6] PREVAIL: A Phase 3 Study of Felzartamab in IgA Nephropathy (NCT06935357) - ClinicalTrials.gov Source
Related Articles
Nipocalimab (Imaavy): The FcRn Blocker That Went Everywhere - From Myasthenia Gravis to the Womb (July 24, 2026)
A day after efgartigimod, meet the other FcRn blocker. Nipocalimab uses the same trick - stop the receptor that recycles your antibodies - but as a full antibody, dosed continuously, and pushed into places no rival has gone: rheumatology, hematology, and even pregnancy.
Rozanolixizumab (Rystiggo): The Subcutaneous FcRn Blocker That Reached Both Myasthenia Serotypes First (July 25, 2026)
Two days after efgartigimod and one after nipocalimab, meet the third FcRn blocker. Rozanolixizumab uses the same trick - stop the receptor that recycles your antibodies - but delivered under the skin, in cycles, and it was the first drug approved to cover both the AChR- and MuSK-antibody myasthenia serotypes. It's also an honest lesson in the mechanism's limits: it failed in CIDP.
Povetacicept (ALPN-303): A Dual BAFF/APRIL Fusion Protein Nears Approval for IgA Nephropathy (September 9, 2026)
Povetacicept (ALPN-303) is an investigational once-monthly fusion protein that blocks both BAFF and APRIL, the cytokines that keep antibody-producing B cells alive. Built from an engineered TACI decoy fused to an antibody Fc, it targets the B-cell driver of IgA nephropathy. A positive Phase 3 RAINIER interim analysis and an FDA accelerated-approval filing (PDUFA November 30, 2026) have made it one of the most closely watched biologics in nephrology.
Sibeprenlimab (VOYXACT): The First APRIL-Targeted Antibody Approved for IgA Nephropathy (September 10, 2026)
Sibeprenlimab (VOYXACT, sibeprenlimab-szsi) is a humanized monoclonal antibody that neutralizes APRIL, the cytokine that drives the antibody-producing B cells behind IgA nephropathy. In the pivotal Phase 3 VISIONARY trial - the largest ever run in IgAN - it cut proteinuria by roughly half and appeared to preserve kidney function, earning the first FDA accelerated approval of an APRIL-targeted therapy for the disease in November 2025. Given as a 400 mg subcutaneous injection once every four weeks, it marks a new era of targeted treatment for a leading cause of kidney failure in young adults.